Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid Diagnostics” or “Lucid”), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that, yesterday, the MolDX Program (“MolDX”) published a Future Effective Local Coverage Determination (“LCD”) L39256, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 14, 2023. This foundational LCD, entitled “Molecular Testing for(…..) Continue reading »